ALXO

Company Overview — What Does ALX ONCOLOGY HOLDINGS INC Do?

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California. ALX ONCOLOGY HOLDINGS INC (ALXO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jaume Pons and employs approximately 40 people. With a market capitalization of $261M, ALXO is one of the notable companies in the Healthcare sector.

ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Rating — Reduce (April 2026)

As of April 2026, ALX ONCOLOGY HOLDINGS INC receives a Reduce rating with a composite score of 30.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ALXO ranks #3,543 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ALX ONCOLOGY HOLDINGS INC ranks #560 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ALXO Stock Price and 52-Week Range

ALX ONCOLOGY HOLDINGS INC (ALXO) currently trades at $1.70. The 52-week high for ALXO is $2.66, which means the stock is currently trading -36.1% from its annual peak. The 52-week low is $0.40, putting the stock 320.8% above its annual trough. Recent trading volume was 2.6M shares, reflecting moderate market activity.

Is ALXO Overvalued or Undervalued? — Valuation Analysis

ALX ONCOLOGY HOLDINGS INC (ALXO) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 9.27x, versus the sector average of 2.75x.

At current multiples, ALX ONCOLOGY HOLDINGS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ALX ONCOLOGY HOLDINGS INC Profitability — ROE, Margins, and Quality Score

ALX ONCOLOGY HOLDINGS INC (ALXO) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -421.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -185.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ALXO Debt, Balance Sheet, and Financial Health

ALX ONCOLOGY HOLDINGS INC has a debt-to-equity ratio of 39.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.07x, indicating strong short-term liquidity. Total debt on the balance sheet is $10M. Cash and equivalents stand at $23M.

ALXO has a beta of 1.00, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ALX ONCOLOGY HOLDINGS INC is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ALX ONCOLOGY HOLDINGS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, ALX ONCOLOGY HOLDINGS INC reported revenue of $0 and earnings per share (EPS) of $-1.90. Net income for the quarter was $-110M. Operating income came in at $-114M.

In FY 2025, ALX ONCOLOGY HOLDINGS INC reported revenue of $0 and earnings per share (EPS) of $-1.90. Net income for the quarter was $-102M. Operating income came in at $-104M.

In Q3 2025, ALX ONCOLOGY HOLDINGS INC reported revenue of $0 and earnings per share (EPS) of $-0.41. Net income for the quarter was $-22M. Operating income came in at $-23M.

In Q2 2025, ALX ONCOLOGY HOLDINGS INC reported revenue of $0 and earnings per share (EPS) of $-0.49. Net income for the quarter was $-26M. Operating income came in at $-27M.

Over the past 8 quarters, ALX ONCOLOGY HOLDINGS INC has experienced revenue contraction from $0 to $0. Investors analyzing ALXO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ALXO Dividend Yield and Income Analysis

ALX ONCOLOGY HOLDINGS INC (ALXO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ALXO Momentum and Technical Analysis Profile

ALX ONCOLOGY HOLDINGS INC (ALXO) has a momentum factor score of 66/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 27/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ALXO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ALX ONCOLOGY HOLDINGS INC (ALXO) ranks #560 out of 838 stocks based on the Blank Capital composite score. This places ALXO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ALXO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALXO vs S&P 500 (SPY) comparison to assess how ALX ONCOLOGY HOLDINGS INC stacks up against the broader market across all factor dimensions.

ALXO Next Earnings Date

No upcoming earnings date has been announced for ALX ONCOLOGY HOLDINGS INC (ALXO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ALXO? — Investment Thesis Summary

The quantitative profile for ALX ONCOLOGY HOLDINGS INC suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Price momentum is positive at 66/100, suggesting the trend favors buyers. High volatility (stability score 31/100) increases portfolio risk.

In summary, ALX ONCOLOGY HOLDINGS INC (ALXO) earns a Reduce rating with a composite score of 30.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALXO stock.

Related Resources for ALXO Investors

Explore more research and tools: ALXO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALXO head-to-head with peers: ALXO vs AZN, ALXO vs SLGL, ALXO vs VMD.